news/
94 pages · Updated July 26, 2026
Pages
- Insilico Medicine Announces 2025 Annual Results, Redefining Value Delivery in AI-Powered Drug Discovery
- BIO Europe 2025 | Pushing the frontiers of generative AI for longevity, Insilico unveils portfolio of unique multiparameter-optimized cardiometabolic assets
- Insilico Medicine Integrates Nach01 Foundation Model with Microsoft Discovery to Enable AI-Native, Enterprise-Ready Drug Discovery Workflows
- Insilico Medicine Nominates ISM6200, a Potential Best-in-class Selective NR3C1 Inhibitor for Ovarian cancer, Cushing’s Syndrome, Hypercortisolism-associated obesity and Glaucoma
- Insilico Announces Nature Medicine Publication of Phase IIa Results of Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis Discovered and Designed with a Pioneering AI Approach
- Insilico Medicine and Taigen achieves license agreement to develop and commercialize AI-driven PHD inhibitor for anemia of Chronic Kidney Disease (CKD)
- JMC Publication: Insilico’s AI platforms enable discovery of potent, selective, oral DGKα inhibitor to overcome checkpoint resistance
- Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
- JMC Publication: Insilico’s Chemistry42 empowered efficient discovery of potent, oral CBLB inhibitor for immuno-oncology
- Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase IIa Trial for Garutadustat, the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
- Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
- Liquid AI and Insilico Medicine Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery
- 404 | Insilico Medicine
- Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
- Nature Communications: Insilico Medicine presents AI-empowered dual-action PROTAC targeting PKMYT1
- Leveraging Chemistry42, Insilico nominates ISM3830 as preclinical candidate targeting CBLB for advanced tumors immunotherapy
- Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment
- Insilico Medicine, Mabwell Bioscience, and ChemExpress forging ahead with ADC innovation through strategic collaboration
- AI-Powered R&D Acceleration: Insilico Medicine and Hisun Pharma Nominate a Preclinical Candidate Just 8 Months After Forming a Strategic Collaboration
- Insilico Medicine Showcases Preclinical Breakthroughs for Four AI-Powered Oncology Pipelines at AACR Annual Meeting 2026
- Insilico Pharma.AI fall launch recap: Understand latest AI updates for healthcare research with frequent questions answered
- Pharma.AI Q2 2026 Summer Webinar: A Deep Dive into Insilico Medicine’s Latest Platform Upgrades
- Advancing Drug Discovery from Automation to Autonomy: Insilico Medicine Announces LabClaw the Intelligent System
- Insilico Medicine’s Pharma.AI Q4 Winter Launch Recap: Revolutionizing drug discovery with cutting-edge AI innovations, accelerating the path to pharmaceutical superintelligence
- Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
- Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science
- Pharma.AI Webinar 2026 | Deciphering the Spring Kickoff Updates from Insilico Medicine
- Insilico Medicine caps monumental week at BIO 2026: Secures landmark $2.5B partnership and dominates thought leadership
- Pharma.AI Summer Update Preview: Drive the future of pharmaceutical intelligence
- Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
- Insilico Medicine’s CEO Dr. Alex Zhavoronkov recognized among global top one per cent for pharmacology and toxicology
- Pharma.AI Spring Kickoff 2026: Drive the Future of Pharmaceutical Intelligence
- Insilico’s Rentosertib Inhalation Solution Receives IND Clearance for the World’s First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
- Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
- Insilico Medicine and Saudi Aramco Introduce the “Sanity Pipeline” to Advance AI-driven Discovery of MOFs
- Insilico Pilots the Automated AI-driven Partnering System for Biotechnology Assets and AI Platforms
- Insilico Medicine Appoints Jue Wang, PhD as Global Head of Business Development
- Insilico Medicine Advances AI-Driven Target Discovery with Validated TargetPro–TargetBench Framework
- Insilico Medicine Featured in Harvard Business School Case on Rentosertib
- Insilico Medicine to Announce 2025 Financial Results on March 30, 2026
- Meet us at BIO-Europe | Insilico to showcase generative AI platform and introduce cardiometabolic portfolio at BIO-Europe 2025 in Vienna
- ACS Central Science | Researchers from Insilico Medicine and Lilly publish foundational vision for fully autonomous “Prompt-to-Drug” pharmaceutical R&D
- Insilico Open-sources DORA on GitHub, supported by Microsoft Azure, Transforming Scientific Research and Content Creation with Multi-Agent LLMs
- Insilico Medicine Announces Industry’s First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery
- Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate
- Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines
- Insilico Medicine Initiates AI-Driven Collaboration with Leading Global Cancer Center to Identify Novel Targets for Gastroesophageal Cancers
- Join Insilico Medicine at NeurIPS 2025: Unveiling generative AI breakthroughs revolutionizing drug discovery and development
- AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases
- Insilico Medicine Nominates Pan-KRAS Preclinical Candidate ISM6166 to Tackle “Undruggable” Solid Tumors, Showing Tumor Regression in Preclinical Studies
- Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery
- Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women’s Health
- Insilico Medicine named to Fast Company’s annual list of the world’s most innovative companies of 2026
- Insilico Medicine to Showcase at WHX 2026, Bridging Middle East–Global Partnerships to Accelerate Translational Research
- Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million
- Insilico Medicine unveils winter edition of Pharma.AI, accelerating the path to pharmaceutical superintelligence
- Transforming Drug Target Discovery, Insilico Medicine Publishes Landmark Paper Introducing AI-empowered Target Identification Pro (TargetPro) and TargetBench 1.0
- Insilico Medicine CEO Alex Zhavoronkov to speak on longevity and AI in healthcare at Fortune Global Forum in Riyadh
- ARDD for healthy longevity: How science, technology and investment are redefining the future
- Insilico showcases advanced generative biologics engine in breakthrough 72-hour peptide design targeting GLP1R for cardiometabolic disease
- Insilico Medicine Announces US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
- Insights to Innovation: Insilico Medicine AI-driven Practice Published on Springer Nature in Latest AI for Drug Discovery Volume
- Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor
- Insilico Medicine Receives USD 5 Million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
- Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology
- Insilico Medicine Announces Global R&D Collaboration with Lilly
- Insilico Medicine and Atossa Therapeutics publish AI-driven study in Nature's Scientific Reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma
- Insilico Medicine leadership to attend 44th Annual J.P. Morgan Healthcare Conference
- Insilico Medicine named a 2025 BostInno Fire Awards honoree
- Meet us at PFF Summit 2025 | Insilico Medicine to showcase generative AI platform and introduce their latest AI-driven Pulmonary Fibrosis clinical research at PFF Summit 2025 in Chicago, IL
- Insilico employs AI-driven tools to uncover the link between idiopathic pulmonary fibrosis (IPF) and accelerated aging
- AI power for future growth: Insilico leadership team to speak at FII 2025
- Pharma.ai summer 2025 updates: Join Insilico Medicine on July 10 for the future of AI-empowered medical research boost
- On-demand recording and key takeaway available: Insilico introduces generative AI platform enhancements across drug discovery stages in Pharma.ai summer updates webinar
- Transforming Parkinson’s disease treatment, Insilico Medicine announces IND-enabling completion for AI-empowered oral NLRP3 inhibitor ISM8969
- Insilico ranked Top50 in USA in Nature Index’s “2025 Research Leaders: Global corporate institutions for all-subject output”
- Showcasing gen-AI breakthroughs, Insilico Medicine presents fall edition of Pharma.AI quarterly launch
- Observer AI Power Index: Alex Zhavoronkov, PhD, founder of Insilico Medicine acknowledged among 100 future-shaping leaders
- Insilico Medicine launches Nach01 Foundation model on AWS Marketplace to help accelerate generative chemistry innovation
- JMC | Insilico Medicine publishes AI-driven innovative design strategy for highly selective FGFR2/3 inhibitors
- Insilico and Lilly enter a research and licensing collaboration to advance AI-driven drug discovery
- Towards pharmaceutical super intelligence: During BioHK 2025, Insilico Medicine gathers industry leaders to shape the future of AI in healthcare
- AI for Good Global Summit: Dive into the future potential of generative AI with Alex Zhavoronkov PhD, Insilico’s founder and CEO
- Insilico Medicine announces positive topline results of ISM001-055 for the treatment of idiopathic pulmonary fibrosis (IPF) developed using generative AI
- Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
- Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025’s Largest Hong Kong Biotech IPO
- Press Releases | Insilico Medicine
- Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
- Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
- Insilico Medicine to Present 3 Abstracts at the 2026 Crohn’s & Colitis Congress Highlighting Clinical, Preclinical Safety, and Efficacy Data for ISM5411, a Novel Gut-Restricted PHD1/2 Inhibitor
- Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI
- Up to 31.3% Body Weight Loss, Insilico Medicine Nominates AI-Powered GIPR Antagonist ISM0676 as Preclinical Candidate, Showing Synergistic Efficacy in Combination Therapy
- Insilico and TaiGen achieve milestone in collaboration: Out-licensed CKD anemia candidate ISM4808 completes first human enrollment and dosing in Phase I clinical trial
- Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery